Atossa Therapeutics (ATOS) Issues New U.S. Patent

Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations.

This newly granted patent further fortifies Atossa’s intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, encompassing novel compositions and methods related to (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM). Specifically, the patent covers enteric oral formulations of (Z)-endoxifen and salts thereof as well as their use in treating hormone-dependent breast and reproductive tract disorders.

“The issuance of U.S. Patent No. 12,275,684 marks a significant milestone in our mission to advance innovative treatments for breast cancer. This patent not only reinforces our commitment to protecting our intellectual property but also underscores our dedication to delivering effective therapeutic options to patients,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “We remain steadfast in our pursuit of scientific excellence and patient-centered solutions to address the persisting unmet medical needs in breast cancer treatment and prevention.”

Atossa's robust patent estate now includes multiple U.S. patents, collectively encompassing over 100 claims related to (Z)-endoxifen formulations and their clinical applications. This comprehensive and ongoing protection strategy bolsters the company's continued leadership in developing targeted therapies for hormone receptor-positive breast cancer.​

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• ACI Worldwide exploring sale of billing division - Reuters
• Hyperscale Data declares preferred stock dividends for August